We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Protein Patterns in Blood Can Predict IBD As Early As 16 Years Before Diagnosis

By LabMedica International staff writers
Posted on 27 Nov 2024

Inflammatory bowel disease (IBD) is particularly challenging because it can progress for years without showing symptoms, leading to damage in the gastrointestinal tract before treatment begins. More...

Now, scientists have discovered specific protein patterns in blood that can predict IBD up to 16 years before it is diagnosed. This is especially true for Crohn’s disease, which can be detected with remarkable accuracy.

Researchers at Örebro University (Örebro, Sweden) analyzed nearly 800 blood samples and identified distinct protein patterns that differentiate healthy individuals from those who later develop Crohn’s disease or ulcerative colitis. Their findings revealed that a particular combination of 29 proteins could predict Crohn’s disease with high accuracy. In contrast, predicting ulcerative colitis proved to be more difficult. The study showed that changes in protein patterns could be detected in individuals with Crohn’s disease as early as 16 years before diagnosis. According to the research published in Gastroenterology, the results emphasize that proteins related to intestinal barrier function and the immune system play a critical role in understanding the development of Crohn’s disease.

“We’ve taken an important step towards us being able to predict and prevent these diseases at a very early stage in the future,” said Jonas Halfvarson, professor of gastroenterology at Örebro University, and lead researcher of the study. “By discovering these markers long before symptoms make themselves known, we can potentially intervene earlier and hopefully improve quality of life for those individuals that risk developing IBD.”


Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Online QC Software
Acusera 24•7
Automated Clinical Chemistry Analyzer
Envoy 500+
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.